Overview
Next-generation long-read whole genome sequencing integrating genomic and epigenomic biomarkers in one assay.
Why this Test Matters
Precision oncology depends on identifying clinically actionable genomic alterations. This assay helps clinicians select targeted therapies, evaluate immunotherapy eligibility, identify prognostic biomarkers, detect resistance mechanisms, and match patients to suitable clinical trials while minimizing sequential testing.
Who Should Consider this Test?
● Relapsed cancer ● Panel/WES negative cases ● Complex genomes
Applicable Cancer Types
Most solid tumors and Liquid cancers AML/CML
What is Covered?
- SNVs
- InDels
- SVs
- CNVs
- CpG methylation
- MSI
- TMB
- Tumor purity
- Mutational signatures
Clinical Utility
- Treatment selection
- Prognostic and predictive biomarkers
- Clinical trial matching
- Identification of actionable alterations
- Comprehensive clinical interpretation
Technology
PacBio HiFi Long-read WGSkey Features
| Parameter | Details |
|---|---|
|
Sample Type |
Fresh tumor + matched blood |
|
Samples |
Tumor ± normal |
|
Turnaround Time |
~14 working days |
|
Report Includes |
Variant interpretation, therapy associations, clinically actionable biomarkers |
|
Quality |
High-depth NGS with rigorous QC |